JP6001557B2 - 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 - Google Patents

抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 Download PDF

Info

Publication number
JP6001557B2
JP6001557B2 JP2013549652A JP2013549652A JP6001557B2 JP 6001557 B2 JP6001557 B2 JP 6001557B2 JP 2013549652 A JP2013549652 A JP 2013549652A JP 2013549652 A JP2013549652 A JP 2013549652A JP 6001557 B2 JP6001557 B2 JP 6001557B2
Authority
JP
Japan
Prior art keywords
seq
antibody
ptprs
human
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013549652A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014524733A (ja
JP2014524733A5 (cg-RX-API-DMAC7.html
Inventor
智英 山崎
智英 山崎
ザオ、ジン
晃司 石田
晃司 石田
恭枝 柴田
恭枝 柴田
チョウ、ミンクウォン
まゆき 遠藤
まゆき 遠藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBI Biotech Co Ltd
Original Assignee
SBI Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co Ltd filed Critical SBI Biotech Co Ltd
Priority to JP2013549652A priority Critical patent/JP6001557B2/ja
Publication of JP2014524733A publication Critical patent/JP2014524733A/ja
Publication of JP2014524733A5 publication Critical patent/JP2014524733A5/ja
Application granted granted Critical
Publication of JP6001557B2 publication Critical patent/JP6001557B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
JP2013549652A 2011-04-28 2012-04-27 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体 Active JP6001557B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013549652A JP6001557B2 (ja) 2011-04-28 2012-04-27 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2011101752 2011-04-28
JP2011101752 2011-04-28
PCT/JP2012/061795 WO2012148003A1 (en) 2011-04-28 2012-04-27 ANTI-HUMAN RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE σ ANTIBODY
JP2013549652A JP6001557B2 (ja) 2011-04-28 2012-04-27 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016170634A Division JP6412072B2 (ja) 2011-04-28 2016-09-01 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体

Publications (3)

Publication Number Publication Date
JP2014524733A JP2014524733A (ja) 2014-09-25
JP2014524733A5 JP2014524733A5 (cg-RX-API-DMAC7.html) 2015-07-16
JP6001557B2 true JP6001557B2 (ja) 2016-10-05

Family

ID=46147004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013549652A Active JP6001557B2 (ja) 2011-04-28 2012-04-27 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体
JP2016170634A Active JP6412072B2 (ja) 2011-04-28 2016-09-01 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016170634A Active JP6412072B2 (ja) 2011-04-28 2016-09-01 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体

Country Status (16)

Country Link
US (2) US9803026B2 (cg-RX-API-DMAC7.html)
EP (2) EP3232202B1 (cg-RX-API-DMAC7.html)
JP (2) JP6001557B2 (cg-RX-API-DMAC7.html)
KR (1) KR101873614B1 (cg-RX-API-DMAC7.html)
CN (1) CN103703372B (cg-RX-API-DMAC7.html)
AU (2) AU2012248158C1 (cg-RX-API-DMAC7.html)
CA (1) CA2834243C (cg-RX-API-DMAC7.html)
ES (2) ES2788183T3 (cg-RX-API-DMAC7.html)
HU (2) HUE054211T2 (cg-RX-API-DMAC7.html)
IL (1) IL229127A (cg-RX-API-DMAC7.html)
MX (1) MX352599B (cg-RX-API-DMAC7.html)
PL (2) PL3232202T3 (cg-RX-API-DMAC7.html)
PT (2) PT2702412T (cg-RX-API-DMAC7.html)
RU (2) RU2013152816A (cg-RX-API-DMAC7.html)
SG (3) SG10202108240VA (cg-RX-API-DMAC7.html)
WO (1) WO2012148003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2173379T1 (sl) 2007-07-02 2015-12-31 Oncomed Pharmaceuticals, Inc. Sestavki in postopki za zdravljenje in diagnosticiranje raka
US9803026B2 (en) * 2011-04-28 2017-10-31 Sbi Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase sigma antibody
AU2012284254B2 (en) 2011-07-15 2015-07-09 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
JP6335896B2 (ja) * 2012-07-13 2018-05-30 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｒｓｐｏ３結合剤およびその使用法
US20150175979A1 (en) 2012-07-23 2015-06-25 La Jolla Institute For Allergy And Immunology Ptprs and proteoglycans in autoimmune disease
US11160873B2 (en) * 2014-02-04 2021-11-02 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
WO2015117199A1 (en) * 2014-02-04 2015-08-13 Monash University Anti-metalloprotease antibody for diagnosis and treatment of cancers
TW201628648A (zh) 2014-09-16 2016-08-16 安可美德藥物股份有限公司 纖維變性疾病之治療
CN107002114A (zh) * 2014-12-18 2017-08-01 豪夫迈·罗氏有限公司 用于确定cdc引发抗体的测定试验和方法
EA201992248A1 (ru) * 2017-03-23 2020-02-06 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
CA3057676A1 (en) * 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
CN112770723B (zh) 2018-07-25 2024-08-02 阿克罗斯生物科学公司 Cldn 18.2特异性单克隆抗体及其使用方法
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members
IL291897A (en) * 2019-10-04 2022-06-01 Albert Einstein College Medicine Kir3dl3 is an inhibitory receptor of the immune system and uses thereof
US20250082734A1 (en) 2021-07-30 2025-03-13 The Regents Of The University Of California Ptprs in autoimmunity
CN114426582B (zh) * 2022-01-07 2022-11-25 陕西脉元生物科技有限公司 一种神经特异性烯醇化酶单克隆抗体及其制备方法和应用
CN116041526B (zh) * 2022-11-14 2023-09-29 华中农业大学 一种鼠抗草鱼IgT单克隆抗体及其制备方法和应用
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
AU2024231685A1 (en) * 2023-03-03 2025-09-25 Case Western Reserve University Cell adhesion molecule targeted immunotherapies
CN118994384B (zh) * 2024-08-09 2025-09-26 陕西脉元生物科技有限公司 抗Ri的人源化单克隆抗体及其应用和基于其的检测方法
CN119874900B (zh) * 2025-03-06 2025-10-17 吉林大学 一种单克隆抗体及其在制备治疗肿瘤药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7847494A (en) 1993-10-01 1995-05-01 New York University Novel receptor-type phosphotyrosine phosphatase-sigma
AU2003252328A1 (en) 2002-08-01 2004-02-23 Ginkgo Biomedical Research Institute Co., Ltd. Method of detecting mouse interferon-producing cells
CN1761682A (zh) * 2003-03-14 2006-04-19 大正制药株式会社 单克隆抗体与产生该单克隆抗体的杂交瘤
WO2005102456A1 (en) 2004-03-27 2005-11-03 The Arizona Board Of Regents On Behalf Of The University Of Arizona Composition and method for cancer treatment
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20070134234A1 (en) 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2009003274A1 (en) * 2007-06-29 2009-01-08 The Hospital For Sick Children Susceptibility gene for inflammatory bowel disease
EP3734281A3 (en) 2008-11-14 2021-01-27 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2011022462A2 (en) * 2009-08-18 2011-02-24 President And Fellows Of Harvard College Neural regeneration
EP2531859A4 (en) * 2010-02-02 2013-07-31 Jolla Inst Allergy Immunolog Compositions and methods of modulating receptor protein tyrosine phosphatases
US9803026B2 (en) * 2011-04-28 2017-10-31 Sbi Biotech Co., Ltd. Anti-human receptor-type protein tyrosine phosphatase sigma antibody

Also Published As

Publication number Publication date
JP2014524733A (ja) 2014-09-25
AU2012248158C1 (en) 2017-02-02
CN103703372B (zh) 2018-01-26
CN103703372A (zh) 2014-04-02
EP3232202A1 (en) 2017-10-18
RU2715642C2 (ru) 2020-03-02
AU2012248158A1 (en) 2014-01-30
WO2012148003A1 (en) 2012-11-01
SG194614A1 (en) 2013-12-30
EP2702412B1 (en) 2017-07-26
RU2017118262A3 (cg-RX-API-DMAC7.html) 2018-11-02
MX2013012393A (es) 2014-04-30
US10730955B2 (en) 2020-08-04
US9803026B2 (en) 2017-10-31
PL2702412T3 (pl) 2018-01-31
SG10201503257WA (en) 2015-06-29
AU2016262677A1 (en) 2016-12-08
AU2012248158B2 (en) 2016-09-08
SG10202108240VA (en) 2021-09-29
MX352599B (es) 2017-11-30
PT2702412T (pt) 2017-11-02
AU2016262677B2 (en) 2018-08-30
KR20140033024A (ko) 2014-03-17
BR112013027631A2 (pt) 2022-01-04
IL229127A0 (en) 2013-12-31
KR101873614B1 (ko) 2018-07-02
US20180155446A1 (en) 2018-06-07
EP3232202B1 (en) 2020-02-19
EP2702412A1 (en) 2014-03-05
ES2638088T3 (es) 2017-10-18
RU2017118262A (ru) 2018-11-02
PL3232202T3 (pl) 2020-10-05
JP6412072B2 (ja) 2018-10-24
HUE054211T2 (hu) 2021-08-30
US20140127223A1 (en) 2014-05-08
CA2834243C (en) 2019-08-27
CA2834243A1 (en) 2012-11-01
PT3232202T (pt) 2020-05-22
HUE034752T2 (en) 2018-02-28
RU2013152816A (ru) 2015-06-10
IL229127A (en) 2017-11-30
JP2017048183A (ja) 2017-03-09
ES2788183T3 (es) 2020-10-20

Similar Documents

Publication Publication Date Title
JP6412072B2 (ja) 抗ヒト受容体型プロテインチロシンホスファターゼσ抗体
JP5420688B2 (ja) 抗ｉｌｔ７抗体
JP7244102B2 (ja) 抗ホスホリパーゼｄ４抗体
BR112013027631B1 (pt) Método para a produção de anticorpo monoclonal ou fragmento que inclui uma região de ligação ao antígeno do mesmo, anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, hibridoma, método para a detecção de uma célula dendrítica plasmocitóide, uso de um anticorpo monoclonal ou um fragmento que inclui uma região de ligação ao antígeno do mesmo, e método ex vivo para suprimir a atividade de uma célula dendrítica plasmocitóide

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160901

R150 Certificate of patent or registration of utility model

Ref document number: 6001557

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250